Disease is a complex interaction between disease-causing agent, host, and the environment. About 90–95% of the public that test positive for coronavirus recover; hence, most of us have inbuilt host response that creates a life-sustaining relationship with coronavirus. Shen and colleagues have used plasma from survivors to study the amplification of host response in severe Covid-19 patients [1]. Modern medicine has been documenting the evidence behind the ancient wisdom—“home of immunity is the gut microbiome” [2]. Hence, we address the scope of understanding host response and immunity during this time of global emergency.
About 433 people die every day from lung cancer in the USA, and 1772 people die per day in the USA from heart disease and many from sepsis, too; such chronic diseases continue to be risk factors for Covid-19 mortality. This illustrates the Dean Ornish and Ayurvedic connection between dysregulated lifestyle, microbiome diversity, chronic disease, and morbidity from communicable and non-communicable disease pandemics. The dysregulation of functional (vpk) forces in the gut apparatus that arise from epigenetic influences accumulates over time, initially asymptomatic in young age and later manifests as hypertension, heart disease, diabetes, migraines, asthma, cancer, and susceptibility to morbidity from infection/dysregulated inflammatory response (Sepsis, etc.) [2].
In our search for an immediate fix to this immune dysregulation in 5–10% of the world population that is critically ill, we are trying to understand the characteristics of the immunity (vpk phenotype assessment) of people who tested positive and survived with good prognosis. Per Brandt, fecal transplants have helped in severe C.diff infections by restoring the gut integrity (aka gut microbiome immunity) from other healthy individuals [3]. There is literature on the experimental use of fecal transplant in sepsis and multi-organ dysfunction syndrome with and without C.diff infection by Wei et al. from China [4, 5]. Our team is considering stool microbiome studies and the role of transplant from healthy donors and milder Covid-positive patients as a compassionate use experimental treatment for critically ill patients. Precautions are necessary because we know that Covid-19 virus is shed in the stool samples of Covid-positive patients. We invite inputs from colleagues on benefit:risk assessment of Covid-19 stool microbiome studies and anecdotal use of FMT such as by Wei et al.
In summary, in the same lines as using convalescent sera from milder Covid patients as a therapy, we are enquiring into potential ongoing considerations for studying the microbiome in Covid-19 as a diagnostic/therapeutic tool.
Declaration
Given that this is a letter to the editor in response to a recent JAMA publication and not an original article, please note the following declarations and the relevance.
Authors’ contributions
Primary author and co-author. The authors read and approved the final manuscript.
Funding
Within local departmental responsibilities. No external funding.
Availability of data and materials
This is a letter to the editor. Data supporting the content of the letter is present as previous literature quoted as references in the manuscript.
Ethics approval and consent to participate
Not relevant or applicable.
Consent for publication
Not relevant or applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Prashanth Thalanayar Muthukrishnan, Email: muthukrp@nychhhc.org.
Robert Faillace, Email: Robert.Faillace@nychhc.org.
References
- 1.Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–9. [DOI] [PMC free article] [PubMed]
- 2.Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570–580. doi: 10.1016/j.ccell.2018.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Brandt LJ. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol Hepatol (N Y) 2012;8(3):191–194. [PMC free article] [PubMed] [Google Scholar]
- 4.Wei Y, Yang J, Wang J, Yang Y, Huang J, Gong H, Cui H, Chen D. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care. 2016;20(1):332. doi: 10.1186/s13054-016-1491-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med. 2019;171:695–702. doi: 10.7326/M18-3635. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
This is a letter to the editor. Data supporting the content of the letter is present as previous literature quoted as references in the manuscript.